ПРОБЛЕМЫ ПОЧЕЧНО-КЛЕТОЧНОГО РАКА: ОТЧЕТ О КОНГРЕССЕ CORE
- Авторы: Попов А.М.1, Калпинский А.С.2, Popov AM3, Kalpinsky AS3
-
Учреждения:
- ФГБУ Медицинский радиологический научный центр МЗ и СР РФ
- ФГУ МНИОИ им. П.А. Герцена
- Выпуск: № 17 (2011)
- Страницы: 82-87
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/279071
- ID: 279071
Цитировать
Полный текст
Аннотация
Представлена информация об основных докладах Конгресса, посвященных лечению распространенного почечно-клеточного рака (ПКР). Были затронуты вопросы применения антиангиогенных препаратов (бевацизумаб, сунитиниб, пазопаниб, сорафениб) и ингибиторов mTOR (эверолимус, темсиролимус), представлены данные об использовании при метастатическом ПКР новых ингибиторов тирозинкиназ, изучаемых в клинических испытаниях (довитиниб и др.). Представлены данные о побочных эффектах таргетной терапии ПКР, путях их профилактики и лечения.
Ключевые слова
Об авторах
Александр Михайлович Попов
ФГБУ Медицинский радиологический научный центр МЗ и СР РФФГБУ Медицинский радиологический научный центр МЗ и СР РФ
Алексей Сергеевич Калпинский
ФГУ МНИОИ им. П.А. ГерценаФГУ МНИОИ им. П.А. Герцена
A M Popov
A S Kalpinsky
Список литературы
- Tortora G. Molecular Signaling Pathways in mRCC and New Treatment Strategies. Conference of renal cancer experts. 8 apr 2011.
- Calvo E. Biomarkers of Patient Response in Advanced RCC: Can We Predict Therapeutic Efficacy? Сonference of renal cancer experts. 8 apr 2011.
- Porta C, Paglino C, De Amici M, et al. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 2010;77(9):809-15.
- Hutson TE, Davis ID, Machiels JH, et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008;26(15):abstr5046.
- Figlin RA. Clinical Updates: VEGFR-TKI Treatment in mRCC. Conference of renal cancer experts. 8 apr 2011.
- Shepard DR, Rini BI, Garcia JA, et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008;26:abstr5123.
- Di Lorenzo G, Carteni G, Autorino R, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009;27:4469-74.
- Oudard S. The Role of mTOR Inhibitors in RCC Management. Conference of renal cancer experts. 8 apr 2011.
- Mulders PFA. The Role of Immunotherapy in RCC. Conference Of Renal cancer Experts. 8 apr 2011
- Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicenter, open-label, randomised phase III trial. Lancet 2008;372:145-54.
- Ravaud A. Safety Issues in RCC Treatment: Applying the Data to Clinical Practice. Conference of renal cancer experts. 9 apr 2011.
- Bamias A. Patient-focused Care: Treating Through Co-morbidities. Conference of renal cancer experts. 9 apr 2011
- Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon (IFN)-alfa in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2009;27:3584-90.
- Escudier B, Eisen T, Stadler W, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
- Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol 2010;28:1061-68.
- Escudier B, Pluzanska A, Koralewski P, et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
- Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204-12.
- Negrier S. Novel Therapies in RCC: Looking Beyond VEGF and mTOR. Conference of renal cancer experts. 9 apr 2011.
- Angevin E, Lin C, Pande AU, et al. A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2010;28(15):3057.
- Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16:311-19.
- Bellmunt J. Ongoing and Future Clinical Trials: Addressing Unmet Needs in RCC. Conference of renal cancer experts. 9 apr 2011.
- Ljungberg B, Cowan N., Hanbury DC, Hora M. et al. Guidelines on renal cell carcinoma 2011. European Association of Urology.
- NCCN clinical practice guidelines in oncology 2011: kidney cancer. National Comprehensive Cancer Network.
Дополнительные файлы
